Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Talquetamab-tgvs + Teclistamab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Talquetamab-tgvs | Talvey | JNJ64407564|JNJ 64407564|JNJ-64407564 | CD3 Antibody 99 | Talvey (talquetamab-tgvs) is a bispecific antibody that targets CD3 and GPRC5D, potentially resulting in increased immune response against GPRC5D-expressing tumor cells (PMID: 32040549). Talvey (talquetamab-tgvs) is FDA-approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov). |
Teclistamab | Tecvayli | JNJ-64007957|BCMAxCD3|JNJ 64007957|JNJ64007957 | CD3 Antibody 99 TNFRSF17 Antibody 20 | Tecvayli (teclistamab) is a bispecific antibody that targets CD3 and BCMA, potentially resulting in increased immune response against BCMA-expressing tumor cells (Blood Dec 2016, 128 (22) 5668). Tecvayli (teclistamab) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04586426 | Phase I | Talquetamab-tgvs + Teclistamab | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | ISR | ESP | CAN | AUS | 2 |
NCT06353022 | Phase II | Talquetamab-tgvs + Teclistamab Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Lenalidomide + Teclistamab | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01) | Not yet recruiting | FRA | 0 |
NCT06208150 | Phase III | Dexamethasone + Elotuzumab + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide Talquetamab-tgvs + Teclistamab Pomalidomide + Talquetamab-tgvs Dexamethasone | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6) | Recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |